We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

First Leukemia Diagnostic Test Based on DNA Sequencing Detects up To 51 Gene Mutations

By LabMedica International staff writers
Posted on 02 Jan 2023
Print article
Image: The Lena Q51 leukemia diagnostic test will be launched in January 2023 (Photo courtesy of Alercell)
Image: The Lena Q51 leukemia diagnostic test will be launched in January 2023 (Photo courtesy of Alercell)

Until recently, a series of blood tests and a bone marrow biopsy were required when someone was "suspected" to have leukemia. It costs thousands of dollars and takes somewhere between six and nine weeks for a diagnosis. In addition to being time consuming, it is a subjective interpretation as cytology remains dependent on human interpretation. Until 2022 the only leukemia tests done could detect two gene mutations. Now, a new leukemia diagnostic test is capable of detecting 51 gene mutations, marking a significant technological and medical advancement.

Alercell, Inc. (Bozeman, MT, USA) is all set to launch LENA Q51(R) in January 2023. LENA Q51 is a leukemia diagnostic test based on sequencing DNA and can detect up to 51 gene alterations in leukemia patients. With LENA Q51, clinicians using a qPCR machine will be able to identify any gene mutations among 51 different genes in just three hours. By doing this, clinicians can determine the gene mutations in three hours via computer, eliminating the need for human interpretation. The information gathered will also enable clinicians to tailor the patient's treatment - all of this at a much lower cost. Alercell also plans to launch LENA S1, the first methylation-based molecular diagnostic test for lung cancer, in the first quarter of 2023. As an epigenetic regulator of gene expression, DNA methylation enables early diagnosis of lung cancer and very accurate localization of the disease, if present.

"I am thrilled that via the application of our knowledge of the genome, we are now able to produce very performing tests that will help people in finally avoiding the unpleasant traditional treatment," said Alercell co-founder Frederic Scheer.

Related Links:
Alercell, Inc.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more